Abstracts tagged "Drug toxicity"

Abstract Number: 2004 • ACR Convergence 2024
Rheumatic Complications Post-CAR-T Cell Therapy. Experience of a Single Center
Jose Alfredo Gomez-Puerta¹, Ana Monegal¹, Andrés Ponce², Pilar Peris³, Nuria Martínez⁴, Valentin Ortiz-Maldonado⁴, Ana Triguero⁴, Carlos Fernández de larrea⁴, Julio Delgado⁴, Raimon Sanmartí Sala¹ and Manuel Juan⁵, ¹Rheumatology Department, Hospital Clinic of Barcelona, Barcelona, Spain, ²Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ³Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ⁴Haematology Department, Hospital Clinic of Barcelona, Barcelona, Spain, ⁵Immunology Department, Hospital Clinic of Barcelona, Barcelona, Spain
Background/Purpose: CAR-T cell therapy is a promising treatment for a range of systemic autoimmune diseases such as systemic lupus erythematosus, systemic sclerosis, and antisynthetase syndrome,…
Abstract Number: 0606 • ACR Convergence 2024
Choice of Biologic Immunotherapy for Psoriasis or Psoriatic Arthritis Not Associated with Risk of Major Adverse Cardiac Events
Bonit Gill¹, Jack Geiger¹, Jean Liew², Michael Putman³ and Shikha Singla¹, ¹Medical College of Wisconsin, Milwaukee, WI, ²Boston University, Boston, MA, ³The Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Individuals with psoriasis or psoriatic arthritis (PsO/PsA) have an elevated risk ofmajor adverse cardiac events (MACE), which include congestive heart failure (CHF), myocardialinfarction (MI),…
Abstract Number: 2121 • ACR Convergence 2024
Increased Fracture Rates in Patients Continuing Methotrexate After Methotrexate-associated Lower Limb Insufficiency Fractures: A Retrospective Follow-up Study
Roba Ghossan¹, OLIVIER FOGEL², Christian Roux¹ and Karine Briot¹, ¹COCHIN HOSPITAL, PARIS, France, ²AP-HP, Paris, France
Background/Purpose: Spontaneous lower limb insufficiency fractures (LLIF) described under prolonged exposure to low-dose methotrexate are often bilateral, multiple, and recurrent. They share a common pathognomonic…
Abstract Number: 0675 • ACR Convergence 2024
Hydroxychloroquine Induced Cardiomyopathy: A Biopsy Proven Case Series
Swetapadma Tripathy¹, Davina Chen², Lanny DiFranza³ and Bibi Ayesha⁴, ¹Montefiore Medical Center, Forest Hills, NY, ²Montefiore Medical Center, New Rochelle, NY, ³Montefiore Medical Center, New York City, NY, ⁴Montefiore Medical Center, Metuchen, NJ
Background/Purpose: Cardiomyopathy is a rare, life-threatening adverse effect of hydroxychloroquine (HCQ) use. There is a paucity in literature regarding treatment and prognosis in these cases. The aim…
Abstract Number: 2165 • ACR Convergence 2024
Fertility Concerns in Adolescents and Young Adults Receiving Gonadotoxic Medications for Rheumatic Disease
SHAHD FARAJALLAH¹, Katie Dunnock², Qing Yu³, Sangeeta Sule⁴ and Tova Ronis⁴, ¹Children's national hospital, Washington DC, ²George Washington University, washington dc, ³George Washington University, washington dc, DC, ⁴Children's National Hospital, Washington, DC
Background/Purpose: Adolescents and young adults diagnosed with rheumatic diseases often require treatment with teratogenic and cytotoxic medications to effectively manage their conditions. While these therapies…
Abstract Number: 1054 • ACR Convergence 2023
Immune Checkpoint Inhibitor Induced Polymyalgia Rheumatica Demonstrates a Similar Scintigraphic Appearance to Classical Polymyalgia Rheumatica on 18F-Fluorodeoxyglucose PET/CT
David Liew¹, Aurora Poon¹, Christopher McMaster², Russell Buchanan¹, Victor Yang¹, Andrew Scott¹ and Claire Owen³, ¹Austin Health, Heidelberg, Australia, ²Austin Health, Pascoe Vale South, Australia, ³Austin Health, Malvern East, Australia
Background/Purpose: Of the rheumatic immune-related adverse events that follow immune checkpoint inhibitor (ICI) cancer immunotherapy, de novo PMR-like episodes without inflammatory arthritis (ICI-PMR) appear to…
Abstract Number: 1919 • ACR Convergence 2023
Arthroplasty Outcomes in Immune Checkpoint Inhibitor-Treated Patients: A Single Center Series
Yasmine Elfarra¹, Edward DiCarlo², Jonathan Vigdorchik², Carlos Aude³, Nilasha Ghosh³, Anne Bass³ and Karmela Kim Chan², ¹Weill Cornell, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Immune checkpoint inhibitors (ICI) have changed the landscape of cancer treatment dramatically, but because of their mechanism of action they are also known to…
Abstract Number: 1056 • ACR Convergence 2023
Immune Checkpoint Inhibitor Rechallenge in Patients Who Previously Experienced Immune-Related Inflammatory Arthritis: A Multicenter Observational Study
Alexandra Ladouceur¹, Gael Mouterde², Alice TISON³, Samuel Bitoun⁴, Sorilla Mary-Prey⁵, Caroline Dutriaux⁶, Emilie Gerard⁵, Anne Pham-Ledard⁵, Marie Beylot-Barry⁵, Maeva Zysman⁵, Rémi Veillon⁵, Charlotte Domblides⁷, Amaury Daste⁷, Marine Gross-Goupil⁷, Baptiste Sionneau⁷, Félix Lefort⁷, Mathieu Larroquette⁷, Thomas Barnetche⁸, Christophe Richez⁹, Marie-Elise Truchetet⁸, Thierry Schaeverbebke¹⁰ and Marie Kostine⁸, ¹Department of Rheumatology of McGill University and CHU-Bordeaux, Montréal, QC, Canada, ²CHU Lapeyronie, Montpellier, France, ³CHU de la Cavale Blanche, Brest, France, ⁴Université Paris-Saclay, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, FHU CARE, Inserm UMR 1184, Paris, France, ⁵Department of Dermatology, Bordeaux University Hospital, Bordeaux, France, ⁶CHU-Bordeaux, Bordeaux, France, ⁷Department of Medical Oncology, Bordeaux University Hospital, Bordeaux, France, ⁸Bordeaux University Hospital, Bordeaux, France, ⁹Université de Bordeaux, Bordeaux, France, ¹⁰University Hospital of Bordeaux, Bordeaux, France
Background/Purpose: Immune checkpoint inhibitors (ICI) improve overall survival in many cancer patients by activating their immune system. However, they can cause off-target immune-related adverse events…
Abstract Number: 2028 • ACR Convergence 2023
Endorsement of Core Domain Definitions to Measure the Impact of Glucocorticoids in Patients with Rheumatic Diseases: A Report from the OMERACT Working Group on Glucocorticoid Impact
Kevin Yip¹, Suellen Lyne², Vasilis Vasiliou³, David Katz⁴, Pamela Richards⁵, Joanna Tieu⁶, Rachel Black⁷, Susan Bridgewater⁸, Dorcas Beaton⁹, lara maxwell¹⁰, Jo Robson⁸, Sarah Mackie¹¹, Catherine Hill⁶ and Susan Goodman¹, ¹Hospital for Special Surgery, New York, NY, ²The Queen Elizabeth Hospital, Adelaide, Australia, ³Royal Holloway, University of London, London, United Kingdom, ⁴Sparrow Pharmaceuticals, Portland, OR, ⁵NA, Bristol, United Kingdom, ⁶The Queen Elizabeth Hospital, Woodville, Australia, ⁷Royal Adelaide Hospital, Adelaide, Australia, ⁸University of the West of England, Bristol, United Kingdom, ⁹Institute for Work & Health, Toronto, ON, Canada, ¹⁰University of Ottawa, Ottawa, ON, Canada, ¹¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Healthcare research has historically been medically oriented, less focused on the patients' perspective that research shows can improve the quality of care. OMERACT advocates…
Abstract Number: 1057 • ACR Convergence 2023
Melanoma and Combination Immune Checkpoint Inhibitors Are More Clearly Associated with the Development of Chronic Inflammatory Arthritis Than Pre-existing Autoimmune Disease: A Cross-Sectional Study of Administrative Health Data
Alexandra Ladouceur¹, Marie Hudson², Hassan Behlouli³, Jeffrey Curtis⁴, Louise Pilote³ and Sasha Bernatsky³, ¹Department of Rheumatology of McGill University and CHU-Bordeaux, Montréal, QC, Canada, ²McGill University, Montréal, QC, Canada, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Immune checkpoint inhibitors (ICIs) improve survival in many malignancies1, by augmenting the immune system's anti-tumor response. However, ICI can result in immune-related adverse events…
Abstract Number: 2453 • ACR Convergence 2023
Development of a Hydroxychloroquine Retinopathy Prediction Score
April Jorge¹, Ronald Melles², Baijun Zhou¹, Yuqing Zhang³ and Hyon K. Choi⁴, ¹Massachusetts General Hospital, Boston, MA, ²Kaiser Permanente Northern California, Redwood City, CA, ³Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ⁴Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: Hydroxychloroquine (HCQ) is an important medication for SLE and other rheumatic diseases, but its major adverse event is HCQ retinopathy. Weight-based HCQ dose is…
Abstract Number: 1058 • ACR Convergence 2023
Resolution of Immune Checkpoint Inhibitors-Induced Inflammatory Arthritis While Maintaining Active Treatment with Checkpoint Inhibitors
Alexandra Ladouceur¹, Thomas Barnetche², Sorilla Mary-Prey³, Caroline Dutriaux⁴, Emilie Gerard³, Anne Pham-Ledard³, Marie Beylot-Barry³, Maeva Zysman³, Rémi Veillon³, Charlotte Domblides⁵, Amaury Daste⁵, Marine Gross-Goupil⁵, Baptiste Sionneau⁵, Félix Lefort⁵, Mathieu Larroquette⁵, Christophe Richez⁶, Marie-Elise Truchetet², Thierry Schaeverbebke⁷ and Marie Kostine², ¹Department of Rheumatology of McGill University and CHU-Bordeaux, Montréal, QC, Canada, ²Bordeaux University Hospital, Bordeaux, France, ³Department of Dermatology, Bordeaux University Hospital, Bordeaux, France, ⁴CHU-Bordeaux, Bordeaux, France, ⁵Department of Medical Oncology, Bordeaux University Hospital, Bordeaux, France, ⁶Université de Bordeaux, Bordeaux, France, ⁷University Hospital of Bordeaux, Bordeaux, France
Background/Purpose: Immune checkpoint inhibitors (ICI) are a revolutionary treatment that boost a patient's own immune system to fight cancer. However, activation of the immune system…
Abstract Number: 2562 • ACR Convergence 2023
Immune Checkpoint Inhibitors-Induced Large Vessel Vasculitis: Data from a Multicenter Study
Adrien Cottu¹, Alessandro Tomelleri², Corrado Campochiaro³, Alexandra Forestier⁴, Jérémie Dion⁵, Milena Bond⁶, Ariane Laparra-ramakichenin⁷, Aline Gury⁸, Xavier Savary⁹, Robin Dhote¹⁰, Albrecht Betrains¹¹, Laurence Bouillet¹², Eric Liozon¹³, Eva Bories¹⁴, Arthur Petitdemange¹, Paul Legendre¹⁵, Benjamin Crichi¹⁶, Philippe Kerschen¹⁷, Lucie Carneiro-Esteves¹⁸, Lucile Grange¹⁸ and Benjamin Terrier¹⁹, ¹Department of Internal Medicine, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, ²Unit of Immunology, Rheumatology, Allergy and Rare Diseases, San Raffaele Scientific Institute, Milano, Italy, ³IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Disease. Vita-Salute San Raffaele University, Milan, Italy, ⁴Department of Medical Oncology, Centre Oscar Lambret, Lille, France, ⁵Internal Medicine Department, Toulouse University Hospital, Toulouse, France, ⁶Azienda sanitaria dell'Alto Adige, Merano, Italy, ⁷Department of Therapeutic Innovations and Early Trials, Gustave Roussy, Université Paris-Saclay, Villejuif, France, ⁸Department of Internal Medicine, Arras GHAT, Arras, France, ⁹Department of Internal Medicine, Brest CHU Hospital, Brest, France, ¹⁰Department of Internal Medicine, Centre Hospitalier Avicenne, Bobigny, France, ¹¹Department of General Internal Medicine, University Hospitals Leuven, Department of Microbiology, Immunology, and Transplantation, KU Leuven, Leuven, Belgium, ¹²Internal medicine department, Grenoble University Hospital, Grenoble, France, ¹³Department of Internal Medicine, University Hospital of Limoges, Limoges Cedex, Limoges, France, ¹⁴Department of Internal Medicine, Purpan CHU Hospital, Toulouse, France, ¹⁵Department of Clinical Immunology, Centre hospitalier du Mans, Le Mans, France, ¹⁶Department of Internal Medicine, Saint Louis Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, ¹⁷Department of Neurology, Luxembourg Hospital Center, Luxembourg City, Luxembourg, ¹⁸Department of Internal Medicine, Centre Hospitalier Universitaire de Saint-Etienne, Saint-Etienne, France, ¹⁹Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France
Background/Purpose: Immune checkpoint inhibitors (ICIs) have dramatically improved the prognosis for many cancers. The therapeutic effect of ICIs is based on their ability to release…
Abstract Number: 1062 • ACR Convergence 2023
Antiretinal Autoantibodies in Hydroxychloroquine Eye Toxicity
Samuel Good¹, Grazyna Adamus², Michael Gorin³, Jordan Jacquez¹, Jennifer Grossman¹, Brian Skaggs¹, Ashira Hasan² and Maureen McMahon⁴, ¹University of California Los Angeles, Los Angeles, CA, ²Oregon Health & Science University, Portland, OR, ³Jules Stein Eye Institute, University of California Los Angeles, Los Angeles, CA, ⁴UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Autoimmune retinopathy (AIR) is a disease process in which circulating autoantibodies (AAbs) against retina-specific antigens cause local inflammation and can lead to blindness. Hydroxychloroquine…
Abstract Number: 1063 • ACR Convergence 2023
Impact of Aging on Rheumatic Immune-related Adverse Events Secondary to Immune Checkpoint Inhibitors: Experience from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO)
Jenny Li¹, Marie Hudson², Carrie Ye³, Janet Roberts⁴, Aurore Fifi-Mah⁵, May Choi⁵, Sabrina Hoa⁶, Thomas Appleton⁷, Janet Pope⁷, Nancy Maltez⁸, Lourdes Gonzalez Arreola⁹, Anthony Obrzut⁹ and Shahin Jamal¹⁰, ¹University of British Columbia, Vancouver, BC, Canada, ²McGill University, Montréal, QC, Canada, ³University of Alberta, Edmonton, AB, Canada, ⁴Dalhousie University, Halifax, NS, Canada, ⁵University of Calgary, Calgary, AB, Canada, ⁶University of Montreal, Brossard, QC, Canada, ⁷University of Western Ontario, London, ON, Canada, ⁸The Ottawa Hospital, Ottawa, ON, Canada, ⁹Arthritis Research Canada, Vancouver, BC, Canada, ¹⁰Vancouver Coastal Health, Vancouver, BC, Canada
Background/Purpose: Immune checkpoint inhibitors (ICI) have revolutionized cancer therapy. Their use is complicated by development of immune-related adverse effects (irAEs), including rheumatic irAEs (Rh-irAE). Aging…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.